|
The laws of nature may be considered as; “the forces and processes that produce and control all the phenomena of the material world.” The sun is a major force in nature and is essential for life on earth, unfortunately the sun also produces some unwanted side-effects for humans. It is fashionable to have a suntan and people feel that exposing their skin to the sun is a healthy, pleasant thing to do. However, the sun also has a “dark side” in that, the ultraviolet part of the electromagnetic spectrum produced by the sun as light, in particular U.V.-B (290-320nm), is responsible for producing long-term solar skin damage (keratosis) and skin cancers. In fact, skin cancers are the most common malignancy in humans. Curaderm-BEC5, is a topical cream preparation of a mixture of the glycoalkaloids solasodine glycosides (BEC). BECs are present in some solanaceous plants, including edible plants such as Solanum melongena (otherwise known as eggplant or aubergine). Now, BEC is available to the public for the treatment of cutaneous solar keratosis, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). This communication gives us some insight how, on the one hand, nature through one of its major forces- sun light, is causing increasingly higher incidences of human skin cancers but, on the other hand, nature, also with the involvement of sunlight and plants has supplied the solution on how to eradicate these skin cancers. The etiologies of keratosis, BCC and SCC, their currently available treatments, and the particular attributes of Curaderm-BEC5 within these concepts of pathogenesis and therapeutics, are presented in this article. Keratosis
An overgrowth of the epidermis forms a scaly layer on the skin. The start of this lesion is usually a small patch of dilated capillaries several millimetres in diameter. Then a dry, rough, adherent yellow or dirty brown scale forms, which may bleed if picked off. It may eventually become thick and horny, with a sharp, clear division between the keratosis and normal skin. Solar keratoses occasionally regress if sun exposure is stopped before they become too established. Although non-malignant, they are potentially malignant and can develop into cancer. Basal Cell Carcinoma (BCC) A BCC is a malignant tumour that rarely spreads to distant sites (metastasises). It starts in the basal layer of cells, between the basement membrane and the subsequent layer of cells and grows upwards from these. It consists of immature cells and has an organized complex of supportive tissue around it. The primary cause of BCC is sunlight exposed onto sensitive skin. Contributory causes are radiation damage, exposure to arsenic, burn scars and vaccination marks. BCCs are the most common malignant skin tumours in humans; they do not spread by metastases, but they erode tissue, and if not treated may eventually kill. BCCs may appear in a variety of guises and on first appearance, they are commonly small, rounded lumps with a pearly edge, and a thin surface covering with a few superficial transparent blood vessels. BCCs may also appear as ulcers, or as bleeding or non-healing lesions. Occasionally they appear as flat diffuse crusting or scaling red lesions. BCC tumours usually grow slowly but in a relentless manner. They then ulcerate and the ulcer will follow the spreading tumour, causing further damage, (for this reason they are also known as rodent ulcers). Squamous Cell Carcinoma (SCC) An SCC is a malignant tumour arising from the cells above the basal layer of the epidermis (prickle layer), usually after many years of exposure to sunlight. The cells in the prickle layer are maturing towards keratin formation and the cancer occurs when they accelerate in growth and breakthrough the basement membrane into the dermis. Although sunlight is the most common cause of SCC, any cancer-producing substance (carcinogen) may initiate its development. SCCs often arise from precancerous conditions such as solar keratoses. SCCs may also develop from skin ulcers, scar tissues, and x-ray damaged tissues, if this occurs then the chance of metastasis increases to approximately 20%. In addition, some 40% of transplant patients who are on immunosuppressive drugs develop SCCs within 5-years post-transplantation. This skin cancer is a serious problem and is potentially deadly. The first sign of an SCC is usually a thickening, with the lesion feeling firm, and the limits are not discrete. In the early stages there may be a crust that may later shed to show an ulcer. It may also form as a crack (fissure) or a small ulcer on the lip, which fails to heal and bleeds recurrently. The SCC may metastasise with an incidence of generally less than 5%.
There are various surgical techniques available to treat skin cancer in its various forms. Surgical excision of a tumour has the advantage, that if done correctly, removes the affected area virtually completely. This treatment is extensive, requires anaesthesia and depending on the tumour, may require skin grafting with its accompanying cosmetic limitations. The risks of surgical intervention are well known and excision of BCCs or SCCs from the facial area often involves reconstructive surgery, which can be both time consuming and costly. Radiotherapy Radiotherapy, moreso prior to the 1950’s than now, has been used to treat most skin cancers. The disadvantage of this mode of treatment is the resulting scar tissue which may be depressed, depigmented and may also undergo degenerative and malignant changes at a later date. Dermatological Dermatological treatment consists of curettage and diathermy/ cauterisation, cryotherapy, chemosurgery and chemotherapy, and is generally used for superficial skin cancers. With curettage and diathermy, the tumour is scraped out and the bleeding stopped by cauterisation, (application of heat) by an electric current (diathermy). Cryotherapy, possibly the most widely used method, involves an intensely cold probe, cooled by liquid nitrogen, which is applied to the lesion. When the lesion thaws, there is pain in the treated area, followed by blister formation. Chemosurgery involves chemical fixation of the lesion and the fixed tissue is shaved off in layers. Chemotherapy with 5-fluorouracil (5-FU), which is an anti-metabolite and inhibits RNA and protein syntheses leading to cell death, is used to treat superficial lesions, but it is not specific for cancer cells. 5-FU is supplied as an ointment and requires considerable care in its application under medical supervision. All of the above methods (surgery, radiotherapy and dermatogical) have their own individual limitations. However, the limitations common to all of these methods are: 1) Formation of scar tissue. 2) Lack of normal tissue regrowth. 3) Limited access to the lesion if it is deep within the skin. 4) A high rate of recurrence. 5) Cosmetic end result. New Specific Treatments It is now well established that specific glycoalkaloids from the Solanum family have anticancer properties. The specific glycoalkaloids consist of BEC, which is a standardised mixture of triglycosides, solasonine and solamargine and their corresponding di- and mono-glycosides (1-12). All the glycosides contain the same aglycone, (the alkaloid without a sugar molecule)- solasodine. Solasodine on its own does not have anticancer properties, however the mono-, di- and triglycosides do have anticancer properties. These glycosides contain a plant sugar rhamnose, which is not usually found in mammalian species. Specific endogenous lectins (EELS), which are specific receptors for the sugar part of the glycoalkaloids and are present in the plasma membranes of susceptible cancer cells but not normal cells recognize and bind the sugar rhamnose of the BEC glycoalkaloids. BEC subsequently enters the cancer cell and causes cell death by destroying the lysosome (6, 13-17). BEC has been shown to have antineoplastic activity in cell culture, animals and in humans (1, 3-12). Currently Phase II studies with BEC are being carried out on terminal internal tumours in man. With these studies BEC in being administered intravenously (18). Precursor of Curaderm-BEC5 A cream formulation of BEC in concentrations of 10% was well tolerated in an open tolerance and dose-finding Phase I and II studies in healthy volunteers and in patients with actinic keratosis, BCC and SCC (3). Application of the cream in this study resulted in swelling of the BCC and SCC lesions, with erythema (reddening) of the surrounding skin, then ulceration in about 2 days, followed over the next weeks by healing with healthy new cell growth. The only reported adverse events were mild itching and burning sensations at the site of the lesions in a few patients. Curaderm-BEC5 In another open study with 72 patients, their treatment with a cream formulation of BEC 0.005% called Curaderm-BEC5, resulted in the regression of all treated lesions (56 actinic keratoses, 39 BCCs and 29 SCCs), with 100% healed after 1 to 13 weeks of treatment (9). There were no lasting therapeutic effects in the 14 patients who received placebo. It is important to note that Curaderm-BEC5 contained extremely low concentrations of BEC (0.005%). One tube of Curaderm containing 20g of cream formulation contained the equivalent of BEC as 5g of eggplant fruit (19). However, for BEC to be effective it must first be purified from its source by a specific process. Unlike other extracts used for therapeutic effects, in which the active ingredients have to be concentrated, with Curaderm-BEC5 the active ingredients in the plant material have to be diluted to still obtain the anticancer effects. In other words, the active glycoalkaloid ingredients are extremely safe as Curaderm-BEC5 contains less glycoalkaloid than the edible eggplant fruit! The following illustrations show various clinical and histological malignant lesions before, during and after Curaderm-BEC5 therapy. Curaderm-BEC5 is applied at least twice daily to the skin and may be applied much more frequently if rapid regression of the tumour is required. Some patients apply the Curaderm-BEC5 cream up to 10 times daily. The cosmetic results after using Curaderm BEC5 are very impressive and over 80,000 patients have now used Curaderm-BEC5 successfully. British clinical trials with Curaderm-BEC5 Recently a double-blind, vehicle-controlled (placebo), randomised, parallel group study of 94 patients was carried out to assess the efficacy and safety of Curaderm-BEC5 in the treatment of patients with BCC. This was a multi-centre Phase III study involving 10 centres in the United Kingdom. The centres were as follows: University of Wales College of Medicine. Leicester Royal Infirmary. The Royal London Hospital. St. Mary’s Hospital. St. Thomas’ Hospital. Royal Free Hospital. Singleton Hospital. Royal Liverpool Hospital. Derriford Hospital. Hope Hospital. The objectives of the study were to evaluate the efficacy and safety of Curaderm-BEC5 in the treatment of BCCs. The primary endpoint was defined as the complete healing of the index lesions, as confirmed by the absence of tumour- determined by clinical and histological examination after 8 weeks of twice daily treatments with Curaderm-BEC5 or placebo. The secondary endpoints were cosmetic evaluation, physician’s global evaluation of response to treatment, assessment of local irritation, reduction in size of the lesion and assessment of the frequency, nature and severity of adverse events. The success rate (complete remission of skin cancers) of the Curaderm-BEC5 cream was 78% within 8-weeks. Longer than the 8 weeks duration therapy with Curaderm-BEC would have resulted in even higher success rates. These results were comparable to those previously obtained and published (4, 5, 13, 14). Not only was it shown that Curaderm-BEC5 was effective in treating superficial BCC, but in a subsequent open study trial comprising 41 patients (carried out at the Dermatology Department at the Royal London Hospital), it was also shown that Curaderm-BEC5 was effective on morpheoic BCC lesions, which are a type of invasive BCC. The clinical trial experience has shown that Curaderm-BEC5 is safe. Only local skin irritation, some pain and erythema (reddening) occurred during treatment. Success was defined as zero presence of BCC after histological (microscopic) examination of samples, removed from the lesion sites by punch biopsy. The conclusion of the dermatologists at the Royal London Hospital is that; “Curaderm-BEC5 is a topical preparation, which is safe and effective and an ideal therapy for outpatient treatment.” They stated further that; “Curaderm-BEC5 is a much-needed alternative to surgery for BCC. This is the most common cancer in Caucasians worldwide and the prevalence continues to increase with an increasing ageing population.” The final conclusion of these investigations was that; “Curaderm-BEC5 is a cost effective treatment for both primary and secondary skin cancer care.” These Phase III and open studies confirm the previously published articles that; Curaderm-BEC5 is the method of choice for treating non-melanoma skin cancers (4, 5, 13, 14). Over 7,000 of the commonly prescribed drugs in the western world are derived from plants. Indeed, the plant kingdom has supplied us with some excellent drugs. Pain sufferers appreciate the relief provided by morphine. Victims of congestive heart failure appreciate the life-saving role of digitoxin or digoxin. Migraine patients experience the dramatic relief effected by ergotamine. Children with leukaemia have recognized the improvement of their condition by treatment with vincristine. Importantly, in addition, the natural plant drugs have served as useful prototypes for even better medicines. Synthetic chemists have been able to convert morphine to hydro-morphone, lysergic acid to methylsergide, cocaine to procaine, physostigmine to neostigmine and even salicin to aspirin. The fact that BEC shows such tremendous promise for treating internal cancers and the fact that Curaderm-BEC5 is now regarded as the method of choice for treating skin cancers lead us to conclude that Curaderm-BEC5 is a primary candidate to be added to the acceptable list of commonly prescribed drugs. Whether synthetic chemists will be able to classify BEC as a useful prototype for terminal internal cancers still remains to be seen. Conclusions • The naturally occurring glycoalkaloids solasodine glycosides (BEC) have anticancer activity in cell culture, animals and in humans. Specific endogenous lectins which are present in the plasma membranes of cancer cells recognize and bind the sugar moiety of BEC. BEC is subsequently internalised and causes cell death by destroying the lysosome. This mode of action is very different than with other anticancer drugs (which are non-specific, destroying normal cells as well) and work on the nuclear contents such as the DNA or RNA of cells. • Independent centres show that Curaderm-BEC5 is virtually 100% effective for treating skin cancers if the lesions are treated for long enough. • The cosmetic result of skin cancer treatment with Curaderm-BEC5 is excellent. • Lesions treated appropriately with Curaderm-BEC5 result in no recurrence. • The amount of BEC in Curaderm is very small. One average-sized egg plant fruit (300g) contains the same amount of BEC as 60 tubes of Curaderm! Thus, Curaderm-BEC is safe as shown by the many published studies. • Curaderm-BEC5 is an ideal therapy for skin cancers. References
0 Comments
There are various forms of treatment conventionally used by medical experts to treat skin cancer. Including:
Surgery Radiotherapy Dermatological Limitations of Conventional Skin Cancer Treatments If you are reading through this information you or someone close to you has probably been diagnosed with a type of skin cancer and interested to know the options you have available to you. The following limitations apply to all commonly used skin cancer treatments:
Curaderm-BEC5 Published Research
Over the last few decades, medical research has been published showing evidence of Curaderm-BEC5 as a safe and effective skin cancer treatment Highly respectable journals such as; Cancer Letters, Drugs of the Future, Asia Pacifc Journal of Pharmacology, Planta Med and Drugs of Today, have published medical research on Curaderm-BEC5 from 1987 and 2003. Such journals are read by medical practioners and scientific researchers so they can be informed of important medicinal developments. Curadern has passed every toxicology and safety data as well as documented the effectiveness of Curaderm-BEC5 to destroy cancer cells with minimal or no cosmetic scarring or unhealthy side effects. The option to treat Skin cancer with Curaderm-BEC5 has been available since 1982. By 2003, when the Phase 3 clinical trials were released, over 80,000 patients had already used and successfully treated their skin cancers with Curaderm-BEC5. So over 80,000 people are testimonial to how well Curaderm-BEC5 works on their skin lesions. Curaderm-BEC5 is an ideal therapy for skin cancer. Curaderm-BEC5 is clinically proven for all types of Non-Melanoma skin cancer. Curaderm-BEC5 is cosmetically effective. Curaderm-BEC5 lowers the percentage of recurrence. Curaderm-BEC5 is safe to use. Curaderm-BEC5 destroys cancer cells without affecting the normal cells. Curaderm-BEC5 treats the Cancer on the surface of the skin tissue and the deep penetrating delivery cream allows the active to penetrate the skin and attack the whole cancer. Skin Cancer Research: The intenationally patented Active Ingredient "BEC" and its capacity to destroy Cancer cells. Formulated with carrier agents to reach cancer infected cells deep in the skin tissue. Ensures skin cancer destruction and healthy skin tissue regrowth. Clinically proven effectivenesss of BEC on Skin Cancer. Published medical research on Curaderm-BEC5. Curaderm-BEC5 Published Research Over the last few decades, medical research has been published showing evidence of Curaderm-BEC5 as a safe and effective skin cancer treatment Highly respectable journals such as; Cancer Letters, Drugs of the Future, Asia Pacifc Journal of Pharmacology, Planta Med and Drugs of Today, have published medical research on Curaderm-BEC5 from 1987 and 2003. Such journals are read by medical practioners and scientific researchers so they can be informed of important medicinal developments. Curadern has passed every toxicology and safety data as well as documented the effectiveness of Curaderm-BEC5 to destroy cancer cells with minimal or no cosmetic scarring or unhealthy side effects. The option to treat Skin cancer with Curaderm-BEC5 has been available since 1982. By 2003, when the Phase 3 clinical trials were released, over 100,000 patients had already used and successfully treated their skin cancers with Curaderm-BEC5. So over 100,000 people are testimonial to how well Curaderm-BEC5 works on their skin lesions. Cham, B.E. (2008). Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides. Research Journal of Biological Sciences 3 (9): 1008-1017
Punjabi, S., Cook, L.J., Kersey, P., Marks, R. and Cerio, R. (2008). Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. International Journal of Dermatology 47(1): 78-82 Cham, B.E. (2007). When does alternative become orthodox? A skin cancer treatment with solasodine rhamnosyl glycosides (BEC): A case study. Proceedings ACAM (Americam College for Advancement in Medicine) Conference. Integrative Medicine: Advancing Science & Clinical Practice. November, Phoenix Arizona USA. Cham, B.E. (2007). Book � The Eggplant Cancer Cure. A Treatment for Skin Cancer and New Hope for Other Cancers from Nature�s Pharmacy. Smart Publications. November. Cham, B.E. (2007). Solasodine Rhamnosyl Glycosides in a Cream Formulation is Effective for Treating Large and Troublesome Skin Cancers. Res. J. Biol. Sci. 2(7), 749-761. Cham, B.E. (2007). Advances in the Eradication of Skin Cancer. Proceedings ICIM Conference � Kentucky USA. Lans, C. (2007). Plants used for cuts, injuries and swelling � S. melongena. Comparison of plants used for skin and stomach problems in Trinidad and Tobago with Asian ethnomedicine. J. Ethnobiol. Ethnomed, 3, 3-12. Shiu, L.Y., Chang, L.C., Liang, C.H., Huang, Y.S., Sheu, H.M. and Kuo, K.W. (2007). Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem. Toxicol. 45(11), 2155-2164. Cham, B. E. (2007). Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers Research Journal of Biological Sciences 2 (4): 503-514, 2007 Hall, C. A., Hobby, T. and Cipollini, M. (2006). Efficacy and Mechanisms of a- Solasonine-and a-Solamargine-Induced Cytolysis on Two Strains of Trypanosoma cruzi. J.Chem. Ecol. 32. 2405-2416 Millward, M., Powell, A., Daly, P., Tyson, S., Ferguson, R. and Carter, S. (2006). Results of phase I clinical trials of Coramsine in patients with advanced solid tumours. J. Clin. Oncol. 24, 2070 Ono, M., Nishimura, K., Suzuki, K., Fukushima, T., Igoshi, K., Yoshimitsu, H., Ikeda, T and Nohara, T. (2006) . Steroidal Glycosides from the Underground Parts of Solanum Sodomaeum. Chem. Pharm. Bull. 54(2)230-233 Amalfi, C. (2006). The little mouse who wouldn�t say die. Cosmos Mag. 471. Nada, C., Nikolic, A., Mihajlo, Z., Stankovic, A. G., Dejan, Z. and Markovic, C. D. (2005). Liquid-liquid systems for acid hydrolysis of glycoalkaloids from Solanum tuberosum L. tuber sprouts and solanidine extraction. Med. Sci. Monit. 11(7), BR200-205. Nada, C., Nikolic, A., Mihajlo, Z., Stankovic, A. G., Dejan, Z. and Markovic, C. D. (2005). Liquid-liquid systems for acid hydrolysis of glycoalkaloids from Solanum tuberosum L. tuber sprouts and solanidine extraction. Med. Sci. Monit. 11(7). BR200-205 Choi, E. and Koo, S. (2005). Anti-nociceptive and anti-inflammatory effects of the ethanolic extract of potato (Solanum tuberosum). Food Agri. Immun. 16. 29-39 Jellinek, N. and Maloney, M. (2005). Escharotic and other botanical agents for the treatment of skin cancer: A review J. Amer. Aca. Dermatol. 53. 486-495 Lequart, V., Goethals, G., Banoub, J., Villa, P. and Martin, P. (2004). An Improved Synthesis of Chacotriose. Chem. Let. 33. 444 Putalun, W., Taura, F., Qing, W., Matsushita, H., Tanaka, H and Shoyama, Y. (2003). Anti-solasodine glycoside single-chain Fv antibody stimulates biosynthesis of solasodine glycoside in plants. Plant Cell Rep. 22. 344-349 Kilman, C. (2004). (2005). Tamanu Oil. A tropical topical remedy. HerbalGram. 63, 26-31. Shen, Y.C., Hung, M.C., Wang, L.T. and Chen, C.Y. (2003). (2005). Inocalophyllins A, B and their methyl esters from the seeds of Calophyllum inophyllum. Chem. Pharm Bull (Tokyo). 51, 802-906. Badami, S., Manohara Reddy, S.A., Kumar, E.P., Vijayan, P. and Suresh, B. (2003). Antitumour activity of total alkaloid fraction of Solanum pseudocapsicum leaves. Phytother. Res. 17. 1001-1004 Chami, L.A., M�ndez, R., Chataing, B., O�Callaghan, J., Usubillaga, A. and LaCruz, L. (2003). Toxicological effects of a-solamargine in experimental animals. Phyto Res. 17, 254-258 Cerio, R. and Punjabi, S. (2002). Clinical Appraisal of BEC5. Barts and The London NHS. Esteves-Souza, A., Silva, T. M. and Alves, C. C. F. et al. (2002). Cytotoxic activities against Ehrlich carcinoma and human K562 leukaemia of alkaloids and flavonoids from two Solanum Species. J. Braz. Chem. Soc. 13. 838-842 Dweck, A.C. and Meadows, T. (2002). Tamanu (Calophyllum inophyllum) � the African, Asian, Polynesian and Pacific panacea. Int. J. Cosmet Sci. 24, 341-348. Vijayan, P., Vinod Kumar, S., Dhanaraj, S. A., Badami, S. and Suresh, B. (2002). In Vitro Cytotoxicity and Anti-tumour Properties of the Total Alkaloid Fraction of Unripe Fruits of Solanum pseudocapsicum. Pharmaceut. Biol. 40. 456-460 Chen, Z. and Miller, A. (2001). Steroidal Alkaloids in solanaceous vegetable crops. (2001). Horticul. Rev. 25. 171-186 Roddick, J. G., Weissenberg, M. and Leonard, A. L. (2001). Membrane disruption and enzyme inhibition by naturally � occurring and modified chaco-triose � containing Solanum steroidal glycoalkaloids. Phyto Chem. 56, 603-610 Morillo, M., Lequart, V., Grand, E., Goethals, G., Usubillaga, A., Villa, P. and Martin, P. (2001). Synthesis of peracetylated chaco-triose. Carbohyd. Res. 334, 281-287 Cipollini, M. L. (2000). Secondary metabolites of vertebrate � dispersed fruits; evidence for adaptive functions. Rev. Chil. Hist. Nat. 73. 421-440 Kuo, K. W., Hsu, S. H., Li, Y. P., Lin, W. L., Liu, L. F., Chang, L. C., Lin, C. C., Lin, C. N. and Sheu, H. M. (2000). Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem. Pharmacol. 60, 1865-1873 Punjabi, S., Cook, I., Kersey, P., Marks, R., Finlay, A., Sharpe, G. et al. (2000). A double blind, multi-centre parallel group study of BEC-5 cream in basal cell carcinoma. Eur. Acad. Dermatol. Venereol. 14 (Suppl), 47-60 Wang, L. and China Hu, Y. (2000). Three kinds of antifungal natural products of the two fungal cells of genetic material. Pharmaceut.J., 35(11), 860-863. Walsh, N. (2000). Promising Topical Therapy for Actinic Keratoses Brief Article Dr S Punjabi. Uni. Liverpool. Family Pratice News. December 1 article. Ali, M.S., Mahmud, S., Perveen, S., Ahmad, V.U. and Rizwani, G.H. (1999). Epimers from the leaves of Calophyllum inophyllum. Phytochemistry. 50, 1385-1389. Cooper, R.A., Molan, P.C. and Harding, K.G. (1999). Antibacterial activity of honey against strains of Staphylcoccus aureus from infected wounds. J. Royal. Soc, Med. 92, 283-285. Molan, P.C. (1999). �The unique properties of manuka honey� Bee informed. J. Amer. Apither. Soc. 6(1), 5-6. Chataing, B., Concepcion, J. L., Lobaton, R. and Usubillaga, A. (1998) Inhibition of Trypanosomer cruzi growth in vitro by Solanum alkaloids; a comparison with ketoconazole. Planta Med. 64, 31-36 Chataing, B., Christancho, N. B. and Usubillaga, A. (1998). Topical treatment of herpes simplex, herpes zoster and genital herpes with a mixture of Solanaceous glycoalkaloids. MedULA. Universidad de Los Andes. 7. 30-34 De Villiers, E.M. (1998). Human papillomavirus infections in skin cancers. Biomed. Pharmacother. 52(1), 26-33. Moss, R. W. (1998). Herbs against cancer History and controversy. Equinax press, Inc. Brooklyn, N.Y. Spino, C., Dodier, M., Nigam, S.K. and Bhargava, K.P. (1998). Anti-HIV coumarins from Calophyllum seed oil. Bioorganic and medicinal chemistry letters 8, 3475-3478. Verpoorte, R. (1998). Exploration of nature�s chemodiversity: the role of secondary metabolites as leads in drug development. Drug Discov. Today 3, 232-238. Verpoorte, R. (1998). Exploration of nature�s chemodiversity: the role of secondary metabolites as leads in drug development. Drug Discov. Today 3, 232-238 Chang, L. C., Tsai, T. R., Wang, J. J., Lin, C. N. and Kuo, K. W. (1998). The rhamnose moity of solamargine plays a crucial role in triggering cell death by apotosis. . Biochem. Biophys. Res. Commun. 242, 21-25 Moss, R. W. (1998). Herbs against cancer History and controversy. Equinax press, Inc. Brooklyn, N.Y. Brady, N.F., Molan, P.C. and Harfoot, C.G. (1997). The sensitivity of dermatophytes to the antimicrobial activity of manuka honey and other honey. Pharmaceut. Sci. 2, 1-3. Cipollini, M. L. and Levey, D.J. (1997). Antifungal activity of Solanum fruit glycoalkaloids: implications for frugivory and seed dispersal. Ecology, 78(3), 799-809. Chataing, B., Concepcion, J.L., Buitrago de Cristancho, N. and Usubilliga, A. (1996). Clinical study of the effectiveness of extracts alkaloids obtained of the fruits of Solanum americanum Miller on Herpes simplex, Herpes two zoster and genital Herpes. Rev. Face. Pharmacy. Univ. The Zandes 32, 18-25. Zur Hausen, H. (1996). Papillomavirus infections-a major cause of human skin cancers. Biochem. Biophys. Acta. 1288(2), F55-78. Hsu, S. H., Tsai, T. R., Lin, C. N., Yen, M. H. and Kuo, K. W. (1996). Solamargine purified from Solanum incanum Chinese herb triggers gene expression of human TNFR1 which may lead to cell apoptosis. Biochem. Biophys. Res. Commun. 229, 1-5 Sussman, L.A.E. and Liggins, D.F. (1996). Incompletely excised basal cell carcinoma: a management dilemma? Aust. NZ. J. Surg. 66, 276-278 Nakamura, T., Komori, C., Lee, Y., Hashinoto, F., Yahara, S., Nohara, T., and Ejina, A. (1996). Cytotoxic activities of Solanum steroidal glycosides. Biol. Biopharm. Bull. 19, 564-566 Cham, B.E., (1995). Solasodine glycosides as anti-cancer agents : Pre-clinical and clinical studies. Proc. 2nd World Congress on Cancer. Indep. Med. Res. 1996; 111-114. Williams, D. G. (1995). The skin cancer cure nobody wants you to know about. Alternatives, 6, 17-22. Mountain Home Publishing. Williams, D. G. (1995). The skin cancer cure so effective, it�s being kept secret. Ingram, TX: Mountain Home Publishing. Cham, B. E. (1994). Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacif. J. Pharmacol. 9, 113-118 Garland, C.F. (1994). Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice. J. Nat. Cancer Inst. 86(10), 798-801. Taylor, P.B., Culp, J.S., Debouck, C., et al. (1994). Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J. Biol. Chem. 269, 6325-6331. Wright, B. (1994). Sunscreens and the protection racket. New Sci. 21-22. Fewell, A.M., Roddick, J.G. and Weissenber, M. (1994). Interactions between the glycoalkaloids solasonine and solamargine in relation to inhibition of fungal growth. Phytochem. 37(4), 1007-1011. Cham, B. E. (1993). Efficacy and mode of action of solasodine glycosides (BEC) on cancer cells. In Proc. 4th Oceania Symposium 0041-51. Editor Mark S. Walker. Bioconcepts Publishing. Mahmud, S., Rizwani, G.R., Ahmad, M., Ali, S., Perveen, S. and Ahmad, V.U. (1993). Antimicrobial studies on fractions and pure compounds of Calophyllum inophyllum Linn. Pakistan J. Pharmacology, 15(2), 13-25. Cham, B. E., Daunter, B and Evans, R. (1992). Topical treatment of malignant and premalignant skin cancers by very low concentration of a standard mixture of solasodine glycosides. Clinical Digest Series. Dermatology. 1992 Garland, C.F., et al. (1992). Could sunscreens increase melanoma risk? Amer. J. Pub. Hlth. 82 (4), 614-165. Cham, B. E., Daunter, B and Evans, R. (1991). Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture of solasodine glycosides. Cancer Letters 59, 183-192 Cham, B. E. (1991). Solasodine glycosides: A new modality for cancer. In Proc. 2nd Oceania Symposium. p.30-36. Editor Mark S. Walker. Bioconcepts Publishing. Daunter, B. and Cham, B. E. (1990). Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters 55, 209-220 Roddick, J. G., R�renber, A. L. and Weissenberg, M. (1990). Membrane-disrupting properties of the steroidal glycoalkaloids Solasonine and Solamargine. Phyto. Chem. 29. 1513-1518 Cham, B. E., Daunter, B. (1990). Solasodine glycosides. Selective cytoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters, 55, 221-225 Cham, B. E., Daunter, B and Evans, R. (1990). Curaderm. Med. J. Australia. 152, 329-330 Cham, B. E., Daunter, B. (1990). Topical treatment of pre-malignant and malignant skin cancers with Curaderm. Drugs of Today 26, 55-58 Cham, B. E. (1989). Curaderm (antineoplastic). Launched in Australia. Drug News and Perspectives 2, 112 Ghazi, M. and Matthees, D. P. (1989). Use of ion-pairing reversed-phase liquid chromathography in separation of solanidine and solasodine. J. Chem. Exol. 15. 2661-2666 Evans, R., Cham, B. E. and Daunter, B. (1989). Letter to the Editor. Your Pharmacy, January Cham, B. E. (1989). Plants yield skin cancer cure. Austral. Technol. Rev. 2, 53 Cham, B. E. (1988). Monograph on the compound BEC. Drugs of the Future. 13, 714-716 Allen, K.L., Molan, P.C., Williams, A.L. and Holland, P.T. (1988). The identification of some antibacterial constituents of New Zealand Manuka honey. J. Agri. Food Chem. 38, 10-13. Cham, B. E., Gilliver, M. and Wilson, L. (1987). Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L. Planta Med. 53, 34-36 Cham, B. E. and Wilson, L. (1987). HPLC of glycoalkaloids from Solanum sodomaeum L. Planta Med. 53, 59-61 Cham, B. E. and Meares, M. M. (1987). Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man. Cancer Letters 36, 111-118 Thorne, H.V., Clarke, G. F. and Skuce, R. (1985). The inactivation of herpes simplex virus by some solanaceae glycoalkaloids. Antiviral Res., 5, 335-343. Jones, P.G. and Fenwick, G.R. (1981). The glycoalkaloid content of some edible Solanaceous fruits and potato products. J. Sci, Food Agric. 32. 419-421 Bhalla, T.N., Saxena, S.K., Misra, G. and Bhargava, K.P. (1980). Calophyllolide-a new nonsteroidal anti-inflammatory agent. Indian J. Medicinal Res. 72, 762-765. Gopalakrishnan, C., Shankaranarayanan, D., Nazimudeen, S.K., Viswanathan, S. and Kameswaran, L. (1980). Depressant activities of xanthones from Calophyllum inophyllum and Mesua Ferrea. Indian J. Pharmacology, 12(3), 181-191. Bajaj, K. L., Kaur, G. and Chada, M. L. (1979). Glycoalkaloid content and other chemical constituents of the fruits of some egg plant (Solanum melongena, L.) varieties. J. Plant Foods, 3, 163-168 Schreiber, K. (1968). Steroidal alkaloids: The Solanum group. In the alkaloids Vol 10, (Mansk, K., Ed.). Academic Press. Jeanson, (1938). Anti-leprous plants not belonging to the flacourtiacees family. Bulletin of National Society of acclimation � France. DON'T BE A STATISTIC.
The incidences of skin cancer are increasing alarmingly worldwide perhaps partly due to global warming. Certain skin cancers can cause you to loose your eye, your nose, your ear or even your life. Curaderm BEC5 is effective at early stages or advanced stages of Skin Cancers. WARNING In the past for monetary reasons, most dermatologists and plastic surgeons did not recommend Curaderm BEC5 and without their endorsement and support the majority of the public wasn't being informed of its availability. As Dr David Williams stated, these professionals make out like bandits living in hog heaven and would be very happy if you never learned about Curaderm BEC5. BEC, the active ingredient in Curaderm BEC5 is a completely natural product. no more surgery, no more scars. Research has proven that the treatment is effective and eliminates the need for repeat surgeries. HATE NEEDLES ? DO NOT WANT FACIAL TISSUE SCARRING ? WANT TO AVOID SURGERY ? THEN CURADERM BEC5 IS THE PRODUCT FOR YOU BEC5 / Curaderm contains a specially purified plant extract from the Solanum Sodomaeum, the so-called Devil's apple- which is found in the Australasia region. The extract, known as Solasodine Glycosides, (0.005%) is also found in smaller quantities in the eggplant and aubergine.
After two decades of research and clinical trials, biochemist, Dr. Bill E. Cham, has discovered that BEC5 when applied topically can eradicate non-melanoma skin cancers, specifically:
Recent trials in 10 UK hospitals found that a twice daily topical application of BEC5 cream to the affected areas gave a complete remission to 78% of the patients within 8-weeks. The remaining 22% of patients had also improved and needed longer treatment times, all this was made possible without chemotherapy, radiotherapy or surgery. The dermatologists at the Royal London Hospital concluded that: "BEC5 is a topical preparation which is safe and effective, an ideal therapy for outpatient treatment... It is a cost effective treatment for both primary and secondary skin cancer care." Furthermore, the histological analyses of biopsies taken before, during and after treatment give compelling evidence of the continuing efficacy of BEC5 because treated skin cancer lesions have not recurred for at least 5 years after cessation of therapy. The figure above shows A) The clinical diagnosis of a BCC on the nose of a patient before treatment with BEC5 - B) During therapy and C) the site of the treated BCC after completion of therapy. The figure above shows a large BCC on the temple. This BCC had been surgically removed and skin grafts applied on two previous occasions, only to return. Just four weeks treatment with BEC5 resulted in full regression and no recurrence after 5-years. Note the cosmetic result. BEC5 cream is therefore recommended to be used to treat areas of the skin that may have become discoloured, thickened or scaly as a result of exposure to sun (UV) light. These areas of the skin are known as keratoses. BEC5 cream is effective to treat true malignant skin cancers such as the non-melanoma basal cell carcinoma and squamous cell carcinoma. To date, it is estimated that more than 80,000 people have used BEC5 and shown below are just some of the results achieved with BEC5 cream: BEC5 works because it contains a plant sugar called rhamnose, (which is not usually found in mammalian species). Specific endogenous lectins, (which are receptors for the sugar part of the glycoalkaloids) are present in the plasma membranes of susceptible cancer cells, but they not present in normal cells. Therefore BEC5 recognizes and binds the sugar rhamnose of the glycoalkaloid to the cancer cell. Subsequently, this enters the cancer cell and causes cell death by destroying the lysosome. Side effects to date have been limited to skin reddening, although during treatment erosion, ulceration and shedding of unwanted skin cells is also likely to take place. Clean the area to be treated with a mild antiseptic (to remove old skin cells). BEC5 should be applied relatively thickly to the area at least twice daily and a micro pore placed over the area. The eyes should be avoided. If any excess occurs, wash and wipe away with cold water. Application should continue for a minimum of 7 days and a maximum of 60 days, this time dependant upon the size, need and regularity of application. BEC5 should not be applied to moles and melanomas. Furthermore, BEC5 should not be used by persons who are allergic to eggplant or aspirin. For full details please see the approved use leaflet below. A 20 ml. bottle of BEC5 can provide enough material to treat one large skin cancer, two medium sized ones, six small ones or twelve sun spots. Apart from the need to "treat" cancer, BEC5's efficacy to help remove and protect against sun spots represents a major step forward in the prevention and "control" of skin cancers. Its ease of use, cost effectiveness, proven efficacy and safety all represent a very significant breakthrough for majority of skin carcinomas, which are by far the most common forms of cancer. What our customers say... I have good news to report. After one month of applying BEC5 twice a day, the lesion is now 50% covered with new tissue. It took me a while to be able to distinguish the new from the old eschar which needed debridement. I had the help of a retired doctor for this. It still burns when I apply it but I can deal with that. For the record the original dime-sized lesion grew to a scarry-looking large quarter size of raw flesh before it started to heal. I did use Neosporin twice for 4 hours only when it was oozing yellow. And I had difficulty keeping it moist when it reached as far as my hairline. But I found that as long as it was totally covered by the Micropore, it was OK. You may pass this on to other intrepid first-time users along with my phone number. It is good to have someone to ask questions of. Thank you so much for encouraging me to do this. It is by far the best approach we have to healing squamous cell carcinoma and keratoses. (Name withheld) Santa Barbara Dr. Jonathan V. Wright, M.D. in Nutrition & Healing Newsletter, July 2007, 14, Issue 5. The skin cancer cure...yes, cure...that works every time. Dr. Cham showed the ICIM group ' before, during, and after ' slides of treatment of multiple instances of BCC and SCC. The cancers were often large ones, from 2 to 6 inches or more in diameter. Yet all of them were gradually healed and replaced by normal tissue in every case! And there was none of the disfigurement often caused by surgery. Breakthrough Treatment for Skin Cancer, BEC5, by Jeffrey Dach MD Posted by Jeffrey Dach MD at 07-16-2007 and is filed under Jeffrey Dach Newsletters A New Discovery Cures Non-Melanoma Skin Cancer. Could there be a better way to eliminate skin cancer without scarring the face? Could there be a medical breakthrough in the treatment of skin cancer? The answer is YES, there is, and it is a skin cream called Cura-Derm or BEC-5 discovered in 1979 and developed by a biochemist in Australia named Bill Cham, PhD. The cream works exceedingly well with non-melanoma skin cancers such as squamous cell and basal cell which are the common varieties. One advantage is that the cancer 'melts away' leaving normal skin with no scarring. Skin cancer involving the lip is an excellent case for the cream since surgery can be disfiguring, while the BEC5 skin cream allows a smoothly healed result. Please note that I have no financial connection with Curaderm or Dr. Cham Curaderm BEC5 is a topical cream that contains a specially purified plant extract from the Solanum Sodomaeum, or Devil's Apple found in Australasia. The extract, known as Solasodine Glycosides, (0.005%) is also found in smaller quantities in eggplant (aubergine). BEC5 was formulated as a result of two decades of research and clinical trials. Biochemist Dr. Cham discovered that when applied topically, BEC5 could eradicate non-melanoma skin cancers, more specifically:-
Numerous clinical trials in Australia and Great Britain have confirmed BEC5's curative ability to regress non-melanoma skin cancers. One open study of 72 patients, culminated in the regression of all treated lesions (56 actinic keratoses, 39 BCCs and 29 SCCs), which were healed completely after 1 to 13 weeks of treatment. Trials in 10 UK hospitals found that in 78% of patients, twice daily topical applications of BEC5 resulted in complete remissions within 8-weeks; with the remaining 22% requiring longer treatment times. Royal London Hospital dermatologists concluded that: "BEC5 is a topical preparation that is safe and effective, an ideal therapy for outpatient treatment... It is a cost effective treatment for both primary and secondary skin cancer care." BEC5 contains a plant sugar called Rhamnose, (which is not usually found in mammalian species). Specific endogenous lectins, (receptors for the sugar part of the glycoalkaloids) are present in the plasma membranes of susceptible cancer cells, but are not present in normal cells. BEC5 recognizes and binds the sugar Rhamnose of the glycoalkaloid to the cancer cell, after which it enters the cancer cell resulting in cell death. BEC5 is non toxic, non mutagenic, and does not interfere with heartbeat or blood flow. Additionally, studies have demonstrated no adverse effects on the liver, kidneys or blood cells both during and after treatment. BEC5 should not be applied to moles and melanomas, and should not be used by persons who are allergic to eggplant or aspirin. What is BEC5?Ty Bollinger: Dr. Wright, tell us about BEC5. What is it? And what does it do? Dr. Wright: BEC5 is a compound derived originally from an Australian plant called devil’s apple. And it’s also found in eggplant and it’s found in green pepper. It was discovered by a doctor - William Cham. He likes to go by Bill. So we all call him Bill. He is a PhD. He is a brilliant guy. He was working at a university in Australia. And someone came out to talk to him—even though his major field is lipid chemistry—they wanted to talk to him because they heard he was interested about why their livestock, when they developed cancer in the eyeball—there’s a certain kind of livestock that developed a lot of that--they go rub themselves up against the devil’s apple plant with their eyes. Damn, their cancer would go away. And so they talked to Dr. Cham about that. And Dr. Cham was intrigued. What does Science know about BEC5 and Cancer CellsDr. Jonathan Wright: he went to research it and he isolated these things called salosodine glycosides. There are two or three of them but they’re all lumped into the name BEC5. BEC5 is Bill Edward Cham-5. So here’s what Dr. Cham found very quickly… What he found is that there was a membrane change in the membrane that surrounds a cancer cell. And if any cancer cell—and as you’ll hear later on from Dr. Gaston, every cancer cell has this membrane change. But normal cells that are not cancerous do not have that membrane change. And the key thing is that the solasodine glycosides, this sugar that sticks down, has a particular type of plant sugar that connects with the cancer cells’ change membrane and it connects. And the cancer cell pulls that stuff inside the cancer cell where it doesn’t mess with the DNA of the cancer cell. It goes to little baggies called lysosomes which are filled with enzymes and they are the storage depot for enzymes that the cell uses. But this stuff, the BEC5, goes into the cancer cell. It goes to the lysosome somehow. It enters the lysosomes, and all the storage membranes are ruptured. And so this cell is flooded with digestive enzymes that digest itself to death. Seriously. Why is Curaderm-BEC5 cream a great choice?Dr. Jonathan Wright: Now, if I have a skin cancer right here and I put it on there, it is not going to hurt the normal skin at all. That is the key thing. This is a beautifully targeted thing. If you heard about the latest thing in cancer treatment is targeting individualization and all that.
7 questions posed to Dr. Richard Lippman regarding his product ACF 228
 The remarkable role of peptide bioregulators for human health(An interview with Professor Vladimir Khavinson) In this interview, the current President of the International Association of Gerontology and Geriatrics, (European Region) and Head of the St. Petersburg Institute of Bioregulation and Gerontology, Professor Vladimir Khavinson, discusses with Phil Micans the role of peptide bioregulators and their ability to create a protective biological reserve for health and aging. PM: “Professor Khavinson, it’s a privilege to talk with you today about the peptide bioregulators that you have discovered.” VK: “Thank you Phil, of course this discovery was the result of much research.” PM: “Indeed, I have read many of your papers and listened to your lectures. But for our readers, could you please describe how it all began?” VK: “The journey began in the 1980s when I was a medical Colonel in the then Soviet army. The Kremlin was concerned about new American weapons such as a battlefield laser that would blind troops, or the fact that our submariners’ and missile silo operators were being exposed to low levels of radiation for long periods. They wanted answers that would help protect and maintain the troops’ health and indeed reverse various conditions. In fact, because of their jobs, some of these individuals were literally showing signs of premature aging; so we could say we were developing an antiaging medicine.” PM: “Fascinating and presumably the resources of the State were behind you?” VK: “Yes they were, and of course it was all a military secret then. I have to say that I don’t believe it would be possible to repeat much of our research today, because then we could virtually ask for what we wanted and it was made available. Today the cost would be very great for pure research- without a known goal.” PM: “So what did you discover?” VK: “We discovered and have widely published that short-chain peptides have a very important role. They are a short-cut to protein synthesis, that each gland/ organ uses a very specific peptide that acts like a gene switch; reinvigorating, triggering if you will a biological reserve. Accordingly, we have named them peptide bioregulators. Importantly we have shown that these peptides can be taken by mouth and make their way into the bloodstream.” PM: “So, by assumption if one was to ingest the peptide bioregulator for the testes, could a man expect more testosterone release, is that the idea?” VK: “Yes and often there are more functions beside, so in your example there is also increased spermogenesis.” PM: “I am aware that these peptide bioregulators today have been patented and are registered on the Russian market as food supplements, how many do you have today and what areas do they cover?” VK: “Regarding the bovine extracted peptides we currently have 17 manufactured on a regular basis; these are peptide extracts from blood vessels, thymus, cartilage, liver, brain, pancreas, pineal, bladder, stomach, eye, testes, heart, ovaries, prostate, adrenals, muscles and kidneys. Naturally we intend to add more as our research continues.” PM: “Have any of these in particular proved to be outstanding in anyway?” VK: “The pineal extract has had many outstanding results as can be seen in our publications, but all peptides to date have been effective.” PM: “I know that the dosing of these peptides is quite unique, for example they don’t have to be taken every day. What do you normally recommend?” VK: “Of course it depends on the need, but the biological reserve is created after a cycled dose and can be maintained for some time thereafter. In nearly every case the biological reserve is improved by 42%. Some individuals who are healthy and wish to maintain health can use as little as 2 capsules daily for 10-days and repeat it 6-months later. Others who require more than just maintenance may need 2 capsules daily for 30-days and repeat bi-monthly, however a lot of patients find their stabilizing dose between those two regimes.” PM: “Have you used peptides in combination and found any synergistic effects?” VK: “We have recently designed up to three peptides for various disorders to make these synergistic combinations. In all cases, the addition of the vascular peptide - Ventfort® - is a useful addition; obviously by improving blood supply this can have wide benefits.” PM: “That’s very useful; IAS will print off that recommended combination list and include it with this interview. Clearly Professor, you have been involved in this fascinating project for many decades, in all that time how many patients do you think it has been applied to and what side effects or contraindications have there been?” VK: “There are no known side-effects, or contraindications and our methods have been applied millions of times in tens of thousands of patients over decades.” PM: “What are your thoughts today about these peptide bioregulators and where they might take the future of medicine and health?” VK: “I think it may improve everyday life of seniors, who constitute the most vulnerable group of population. Europeans and America are getting older and living longer than ever before, nearly 10 years more than in 1960. Increased longevity is a great achievement and a great challenge. It is our task to turn challenges into opportunities and to make the most of the chances offered by the scientific community. Peptides will bring medicine and health systems to a new level with an accent to preventive medicine which will help to enhance human vital resource and add life to years.” PM: “Professor Khavinson thank you very much for your insight into this remarkable research. I firmly believe that peptides are going to become a major focus in our field. Congratulations on your intriguing research.” Introducing The Peptide Revolution - A video about the development of Peptides during the cold war. Russian leadership noted 'Premature Aging Syndrome' in personnel working in certain dangerous conditions and provided the resources for Professors Khavinson and Anisimov to make groundbreaking discoveries. Today Peptides are routinely sold over the counter in Russia and it has taken the West many years to understand and take note of it's interesting properties and effects of the Peptide Revolution.
|
RSS Feed
Information on this email is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Statements have not been evaluated by the Food and Drug Administration.
Copyright © 2005 - 2017
Copyright © 2005 - 2017